» Articles » PMID: 23330615

Blood β-hydroxybutyrate Vs. Urine Acetoacetate Testing for the Prevention and Management of Ketoacidosis in Type 1 Diabetes: a Systematic Review

Overview
Journal Diabet Med
Specialty Endocrinology
Date 2013 Jan 22
PMID 23330615
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: Diabetic ketoacidosis is a life-threatening complication of Type 1 diabetes. Blood β-hydroxybutyrate testing is now widely available as an alternative to urine acetoacetate testing for detecting ketosis. The aim of this study was to review the effectiveness of capillary or serum β-hydroxybutyrate compared with urine acetoacetate testing in prevention and management of diabetic ketoacidosis.

Methods: MEDLINE, EMBASE, EBM Reviews, The Cochrane Library and CINAHL (until April 2012, no language restrictions, studies in humans) were searched for experimental and observational studies comparing the effectiveness of blood β-hydroxybutyrate and urine acetoacetate testing. Outcomes examined were prevention of diabetic ketoacidosis, time to recovery from diabetic ketoacidosis, healthcare costs and patient or caregiver satisfaction. Additional sources included reference lists, conference proceedings and contact with experts in the field.

Results: Four studies (two randomized controlled trials and two cohort studies) met eligibility criteria, including 299 participants across 11 centres. Risk of bias was low to moderate. Blood ketone testing compared with urine testing was associated with reduced frequency of hospitalization (one study), reduced time to recovery from diabetic ketoacidosis (three studies), cost benefits (one study) and greater satisfaction (one study, intervention group only). No study assessed prevention of diabetic ketoacidosis. Meta-analysis could not be performed because of heterogeneity in study design and published data.

Conclusions: There is evidence suggesting that blood β-hydroxybutyrate testing is more effective than urine acetoacetate testing in reducing emergency department assessment, hospitalization and time to recovery from diabetic ketoacidosis, as well as potentially lowering healthcare expenditure. Further research in both young people and adults is needed.

Citing Articles

Narrative review of the role of technology in pediatric diabetes: from testing blood glucose to subcutaneous automated therapy and hope for cure.

Yafi M, Shah A, Velez K Transl Pediatr. 2023; 12(9):1725-1734.

PMID: 37814709 PMC: 10560351. DOI: 10.21037/tp-23-145.


Diabetic Ketoacidosis in Children and Adolescents; Diagnostic and Therapeutic Pitfalls.

Kostopoulou E, Sinopidis X, Fouzas S, Gkentzi D, Dassios T, Roupakias S Diagnostics (Basel). 2023; 13(15).

PMID: 37568965 PMC: 10416834. DOI: 10.3390/diagnostics13152602.


Changes in the gut microbiota of NOD mice in response to an oral Salmonella-based vaccine against type 1 diabetes.

Cobb J, Soliman S, Retuerto M, Quijano J, Orr C, Ghannoum M PLoS One. 2023; 18(5):e0285905.

PMID: 37224176 PMC: 10208495. DOI: 10.1371/journal.pone.0285905.


Utility of plasma beta-hydroxybutyrate to define resolution of diabetic ketoacidosis.

Tremblay E, Millington K, Wu Y, Wypij D, Yang Y, Agus M Pediatr Diabetes. 2022; 23(8):1621-1627.

PMID: 36268546 PMC: 9772128. DOI: 10.1111/pedi.13437.


Potential Clinical Applications for Continuous Ketone Monitoring in the Hospitalized Patient with Diabetes.

Jaromy M, Miller J Curr Diab Rep. 2022; 22(10):501-510.

PMID: 35984565 PMC: 9388986. DOI: 10.1007/s11892-022-01489-6.